Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development

1 Jun 2004

Abstract excerpt

Highly active antiretroviral therapy (HAART) has significantly reduced the number of deaths caused by AIDS. However, the antiviral efficacy of HAART comprising protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) is frequently accompanied by a decrease in patients' quality of life. PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15266894
DOI: 10.1177/095632020401500302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under DevelopmentPMID 15266894Read ↗

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.Semantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance developmentSemantic proximity Read ↗

Antiviral Drug Resistance and the Need for Development of New HIV-1 Reverse Transcriptase InhibitorsSemantic proximity Read ↗

The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV InfectionSemantic proximity Read ↗

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infectionsSemantic proximity Read ↗

Design Strategies of Novel NNRTIs to Overcome Drug ResistanceSemantic proximity Read ↗

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)Semantic proximity Read ↗

Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive reviewSemantic proximity Read ↗

Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse TranscriptaseSemantic proximity Read ↗

Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development.Semantic proximity Read ↗

Emerging reverse transcriptase inhibitors for HIV-1 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.